Viking Therapeutics is a biotech company developing weight loss drugs in the GLP-1 class, with injectable VK2735 in phase 3 trials and an oral candidate entering phase 3 in Q3 2026. The obesity drug market is projected to reach $100 billion by decade's end, currently dominated by Eli Lilly and Novo Nordisk. While Viking stock has shown volatility and room to run from current levels, the article cautions that a single stock is unlikely to make investors millionaires, but could be a valuable addition to a diversified portfolio.

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, announced it will participate in multiple investor conferences in April 2026, including the Raymond James Biotech/BioPharma Conference on April 14 in New York and the Piper Sandler Spring Biopharma Symposium on April 16 in Boston. The company will conduct 1-on-1 meetings with investors at both events.

Viking Therapeutics, a clinical-stage biotech company, is developing VK2735, a dual GLP-1/GIP agonist for weight management currently in phase 3 trials. The company could potentially capture significant market share in the projected $100+ billion weight-loss market if VK2735 demonstrates efficacy comparable to Eli Lilly's Zepbound. However, the company faces substantial risks including clinical setbacks, intense competition, and the historical difficulty most biotechs face in achieving sustained success.

Viking Therapeutics' VK2735, a GLP-1 weight loss drug candidate, could become a major player in the $100 billion weight loss market. Upcoming phase 3 clinical trial results could trigger a threefold stock surge if positive, making Viking an acquisition target. However, the investment is highly binary and risky, with significant downside if trials disappoint.

Viking Therapeutics announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The trial enrolled approximately 1,000 adults with type 2 diabetes and obesity, randomized to receive VK2735 at various doses or placebo for 78 weeks. This marks the second of two registration studies to be fully enrolled, with results expected in 2027.

The weight loss drug market presents significant growth opportunities. Eli Lilly leads the U.S. market with 60% share and generates triple-digit revenue growth from its tirzepatide products. Viking Therapeutics is advancing its VK2735 candidate through clinical trials with strong results. Lilly's stock has dropped 8% this year and trades at 28x forward earnings, potentially offering a buying opportunity, especially with upcoming regulatory decisions on its oral weight loss drug.

ACT Capital Management invested $7.25 million in Viking Therapeutics, acquiring 206,100 shares. Viking, a clinical-stage biotech company, is developing obesity and metabolic disorder treatments, with its lead candidate VK2735 showing promising Phase 2 results of up to 14.7% weight reduction. The company has $706 million in cash runway and is advancing multiple clinical programs including Phase 3 trials.

Eli Lilly strengthened its leading position in the GLP-1 weight loss drug market with two major developments: Novo Nordisk's CagriSema failed to outperform Lilly's Zepbound in clinical trials, and Lilly launched a new convenient monthly-dose pen format for Zepbound. With 60% U.S. market share and a projected $100 billion market over four years, Lilly is well-positioned for continued growth, though competition from Pfizer and Viking Therapeutics remains a potential threat.

Viking Therapeutics' weight-loss drug candidate VK2735 has posted strong mid-stage data and is in phase 3 clinical trials, positioning it as a potential disruptor in the rapidly growing obesity drug market. While the stock could deliver outstanding returns if it successfully navigates clinical and regulatory hurdles, investors should be aware of significant risks including potential clinical setbacks and increased market competition.

Viking Therapeutics (VKTX) shares surged 10.91% after Novo Nordisk's REDEFINE 4 trial failed to demonstrate non-inferiority for its obesity drug CagriSema compared to Eli Lilly's tirzepatide. The trial showed 20.2% weight loss with CagriSema versus 23.6% with tirzepatide. Viking's VK2735, a dual GLP-1/GIP agonist available in both injectable and oral forms, is positioned favorably as it enters Phase 3 trials in Q3 2026, with no competitors currently offering both formulations.

Viking Therapeutics is positioned to capture significant market share in the rapidly expanding weight loss drug market, currently valued at $3.6B with potential to reach $35B if its VK2735 candidate succeeds in phase 3 trials. The obesity drug market is projected to reach nearly $100B by decade's end, with room for multiple competitors beyond current leaders Eli Lilly and Novo Nordisk.

Viking Therapeutics is positioning itself as a serious contender in the rapidly growing weight loss drug market, expected to reach nearly $100 billion by decade's end. The company is advancing its dual GIP/GLP-1 receptor agonist candidate VK2735 through phase 3 trials in both injectable and oral formats, with key data releases and trial launches expected in 2026. While the company shows promise with an innovative pipeline, investors should weigh the clinical development risks against potential long-term growth opportunities.